All In Biotech

Drug Trial Radar · NCT06865430

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Last checked: Nov 20, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Mar 4, 2025

Primary completion

Sep 4, 2025

Study completion Mar 4, 2026

Sponsor

Lead sponsor
Ankara Training and Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Male only, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Holmium Laser Enucleation of the Prostate (HoLEP) is an increasingly popular endoscopic minimally invasive surgical technique for the treatment of benign prostatic hyperplasia (BPH). In the literature, the long-term efficacy and low complication rates of HoLEP have been highlighted in many studies. However, in the early postoperative period, particularly within the first three months, irritative symptoms are reported in 17-35% of cases (1-2). The pathophysiology of postoperative irritative symptoms is not yet fully understood, but it has been suggested that these symptoms may be associated with urethral trauma, the mucosal healing process, and detrusor overactivity. These symptoms can significantly impact quality of life, reducing patient satisfaction. In particular, dysuria is a frequently encountered symptom after HoLEP, with considerable individual variability in its severity and duration. The effectiveness of alpha-blockers in alleviating postoperative dysuria and irritative symptoms remains a topic of debate in the literature. Although prostate tissue is surgically removed, alpha-blockers may improve urinary flow and relieve symptoms associated with bladder outlet obstruction by reducing urethral smooth muscle tone (3). Studies on the use of alpha-blockers following transurethral resection of the prostate (TURP) have shown limited postoperative benefits (4). However, to the best of our knowledge, no study has specifically evaluated their use following HoLEP, an enucleation-based technique. Therefore, further studies are needed to assess the role of alpha-blockers in managing dysuria after HoLEP. The aim of this study is to evaluate the effectiveness of alpha-blocker therapy in managing dysuria and other irritative symptoms following HoLEP. Additionally, the study seeks to determine the impact of this treatment on quality of life and patient satisfaction.

Conditions

  • Prostate Hyperplasia

Interventions

  • Tamsulosin HydrochlorideDrug

    Alpha blockers will be started and symptoms will be questioned.

  • ShamOther

    Patients who were not started on alpha blockers will constitute this group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. dysuria vas score out of 10 pointsTime frame: ONE MONTH
  2. urgency vas score out of 10 pointsTime frame: ONE MONTH
  3. ıpps scoreTime frame: ONE MONTH

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ankara bilkent city hospital

    Ankara, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.